Stock Screener
Stock Research
Market Indexes
Precious Metals
Energy
Commodities
Interest Rates
Economy
Global Metrics

Xenetic Biosciences Income from Continuous Operations 2013-2025 | XBIO

Xenetic Biosciences income from continuous operations from 2013 to 2025. Income from continuous operations can be defined as a company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change
  
Xenetic Biosciences Annual Income from Continuous Operations
(Millions of US $)
2024 $-4
2023 $-4
2022 $-7
2021 $-6
2020 $-11
2019 $-13
2018 $-7
2017 $-4
2016 $-54
2015 $-13
2014 $-14
2013 $-9
2012 $-6
2011 $-6
Xenetic Biosciences Quarterly Income from Continuous Operations
(Millions of US $)
2025-06-30 $-1
2025-03-31 $-1
2024-12-31 $-1
2024-09-30 $0
2024-06-30 $-1
2024-03-31 $-1
2023-12-31 $-1
2023-09-30 $-1
2023-06-30 $-1
2023-03-31 $-1
2022-12-31 $-1
2022-09-30 $-1
2022-06-30 $-3
2022-03-31 $-2
2021-12-31 $-2
2021-09-30 $-1
2021-06-30 $-1
2021-03-31 $-1
2020-12-31 $-1
2020-09-30 $-8
2020-06-30 $-1
2020-03-31 $-1
2019-12-31 $-1
2019-09-30 $-9
2019-06-30 $-1
2019-03-31 $-1
2018-12-31 $-2
2018-09-30 $-2
2018-06-30 $-2
2018-03-31 $-2
2017-12-31 $4
2017-09-30 $-2
2017-06-30 $-3
2017-03-31 $-3
2016-12-31 $0
2016-09-30 $-2
2016-06-30 $-48
2016-03-31 $-4
2015-12-31 $-4
2015-09-30 $-5
2015-06-30 $-1
2015-03-31 $-2
2014-12-31 $-4
2014-09-30 $-3
2014-06-30 $-3
2014-03-31 $-4
2013-12-31 $-4
2013-09-30 $-3
2013-06-30 $-1
2013-03-31 $-1
2012-12-31
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $0.005B $0.003B
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Additionally, Xenetic is leveraging PolyXen(TM), its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen(TM) has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.
Stock Name Country Market Cap PE Ratio
Chugai Pharmaceutical (CHGCY) Japan $70.494B 27.11
Zoetis (ZTS) United States $69.411B 25.18
Takeda Pharmaceutical (TAK) Japan $49.383B 10.08
Daiichi Sankyo, - (DSNKY) Japan $48.268B 24.74
BeOne Medicines - (ONC) Switzerland $34.378B 0.00
Sandoz Group AG (SDZNY) Switzerland $27.623B 0.00
Summit Therapeutics (SMMT) United States $19.463B 0.00
Merck (MKKGY) Germany $17.015B 11.06
Shionogi (SGIOY) Japan $14.904B 14.93
United Therapeutics (UTHR) United States $14.084B 12.19
Neurocrine Biosciences (NBIX) United States $13.432B 40.07
IPSEN (IPSEY) France $11.429B 0.00
Orion OYJ (ORINY) Finland $11.336B 27.32
Eisai (ESAIY) $9.286B 10.47
Madrigal Pharmaceuticals (MDGL) United States $9.207B 0.00
Corcept Therapeutics (CORT) United States $7.411B 62.24
Grifols, S.A (GRFS) Spain $6.986B 0.00
Stevanato Group S.p.A (STVN) Italy $6.850B 40.39
Ionis Pharmaceuticals (IONS) United States $6.804B 0.00
Ono Pharmaceutical (OPHLF) Japan $5.740B 19.71
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $5.405B 0.00
Soleno Therapeutics (SLNO) United States $3.644B 0.00
Procaps Group, S.A (PROCF) Luxembourg $3.225B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $3.012B 14.31
Crinetics Pharmaceuticals (CRNX) United States $2.912B 0.00
NewAmsterdam Pharma (NAMS) Netherlands $2.816B 0.00
Catalyst Pharmaceuticals (CPRX) United States $2.580B 8.64
Hypermarcas (HYPMY) Brazil $2.540B 19.10
Centessa Pharmaceuticals (CNTA) United Kingdom $2.278B 0.00
Ocular Therapeutix (OCUL) United States $2.140B 0.00
BioCryst Pharmaceuticals (BCRX) United States $1.797B 0.00
Dyne Therapeutics (DYN) United States $1.790B 0.00
Guardian Pharmacy Services (GRDN) United States $1.633B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.615B 24.06
Avadel Pharmaceuticals (AVDL) Ireland $1.480B 0.00
Ardelyx (ARDX) United States $1.472B 0.00
Harrow (HROW) United States $1.448B 0.00
ARS Pharmaceuticals (SPRY) United States $1.334B 0.00
Evotec AG (EVO) Germany $1.293B 0.00
Xeris Biopharma Holdings (XERS) United States $1.251B 0.00
Enliven Therapeutics (ELVN) United States $1.235B 0.00
Collegium Pharmaceutical (COLL) United States $1.232B 6.73
Cronos Group (CRON) Canada $0.996B 0.00
Akebia Therapeutics (AKBA) United States $0.846B 0.00
Amylyx Pharmaceuticals (AMLX) United States $0.829B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.744B 7.67
ProKidney (PROK) United States $0.705B 0.00
Theravance Biopharma (TBPH) United States $0.701B 57.96
KalVista Pharmaceuticals (KALV) United States $0.670B 0.00
Siga Technologies (SIGA) United States $0.654B 8.08
Relay Therapeutics (RLAY) United States $0.636B 0.00
Bioventus (BVS) United States $0.632B 15.28
Organogenesis (ORGO) United States $0.620B 0.00
Xencor (XNCR) United States $0.600B 0.00
Tourmaline Bio (TRML) United States $0.599B 0.00
USANA Health Sciences (USNA) United States $0.589B 12.07
Elite Pharmaceuticals (ELTP) United States $0.588B 0.00
Oruka Therapeutics (ORKA) United States $0.578B 0.00
Savara (SVRA) United States $0.546B 0.00
Zevra Therapeutics (ZVRA) United States $0.530B 0.00
Nektar Therapeutics (NKTR) United States $0.514B 0.00
Nanobiotix S.A (NBTX) France $0.484B 0.00
Esperion Therapeutics (ESPR) United States $0.438B 0.00
Aquestive Therapeutics (AQST) United States $0.397B 0.00
Aldeyra Therapeutics (ALDX) United States $0.348B 0.00
Tonix Pharmaceuticals Holding (TNXP) United States $0.333B 0.00
4D Molecular Therapeutics (FDMT) United States $0.331B 0.00
Larimar Therapeutics (LRMR) United States $0.324B 0.00
Altimmune (ALT) United States $0.312B 0.00
Nature's Sunshine Products (NATR) United States $0.289B 18.85
AleAnna (ANNA) United States $0.275B 0.00
Lexeo Therapeutics (LXEO) United States $0.265B 0.00
Galectin Therapeutics (GALT) United States $0.263B 0.00
OmniAb (OABI) United States $0.227B 0.00
Heron Therapeutics (HRTX) United States $0.215B 0.00
Lyell Immunopharma (LYEL) United States $0.207B 0.00
Ironwood Pharmaceuticals (IRWD) United States $0.206B 31.75
Aclaris Therapeutics (ACRS) United States $0.195B 0.00
MediWound (MDWD) Israel $0.190B 0.00
Korro Bio (KRRO) United States $0.188B 0.00
China SXT Pharmaceuticals (SXTC) China $0.182B 0.00
Journey Medical (DERM) United States $0.174B 0.00
Innate Pharma SA (IPHYF) France $0.173B 0.00
MEI Pharma (MEIP) United States $0.161B 0.00
Achieve Life Sciences (ACHV) Canada $0.149B 0.00
Profound Medical (PROF) Canada $0.142B 0.00
Inhibikase Therapeutics (IKT) United States $0.141B 0.00
Avalo Therapeutics (AVTX) United States $0.130B 0.00
Avita Medical (RCEL) United States $0.130B 0.00
Protara Therapeutics (TARA) United States $0.120B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.120B 0.00
Cassava Sciences (SAVA) United States $0.106B 0.00
Champions Oncology (CSBR) United States $0.105B 23.84
Dominari Holdings (DOMH) United States $0.100B 0.00
Surrozen (SRZN) United States $0.098B 0.00
Cardiol Therapeutics (CRDL) Canada $0.098B 0.00
ESSA Pharma (EPIX) Canada $0.091B 0.00
Liminatus Pharma (LIMN) United States $0.089B 0.00
BioNxt Solutions (BNXTF) Canada $0.087B 0.00
Pyxis Oncology (PYXS) United States $0.083B 0.00
Context Therapeutics (CNTX) United States $0.080B 0.00
VAXART, INC (VXRT) United States $0.079B 0.00
Wellgistics Health (WGRX) United States $0.079B 0.00
Arch Biopartners (ACHFF) Canada $0.079B 0.00
PMV Pharmaceuticals (PMVP) United States $0.078B 0.00
Assertio Holdings (ASRT) United States $0.076B 0.00
Unicycive Therapeutics (UNCY) United States $0.074B 0.00
Vivani Medical (VANI) United States $0.073B 0.00
Metagenomi (MGX) United States $0.072B 0.00
Nutriband (NTRB) United States $0.072B 0.00
Gain Therapeutics (GANX) United States $0.071B 0.00
Prelude Therapeutics (PRLD) United States $0.070B 0.00
Inotiv (NOTV) United States $0.065B 0.00
DURECT (DRRX) United States $0.060B 0.00
PolyPid (PYPD) Israel $0.056B 0.00
Rafael Holdings (RFL) United States $0.055B 0.00
Karyopharm Therapeutics (KPTI) United States $0.055B 0.00
Jupiter Neurosciences (JUNS) United States $0.053B 0.00
NRx Pharmaceuticals (NRXP) United States $0.052B 0.00
Verrica Pharmaceuticals (VRCA) United States $0.052B 0.00
Fractyl Health (GUTS) United States $0.051B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.049B 29.91
Plus Therapeutics (PSTV) United States $0.048B 0.00
Telomir Pharmaceuticals (TELO) United States $0.047B 0.00
Century Therapeutics (IPSC) United States $0.047B 0.00
Klotho Neurosciences (KLTO) United States $0.046B 0.00
FibroGen (FGEN) United States $0.045B 0.00
Tempest Therapeutics (TPST) United States $0.045B 0.00
Acrivon Therapeutics (ACRV) United States $0.043B 0.00
ElectroCore (ECOR) United States $0.043B 0.00
Reviva Pharmaceuticals Holdings (RVPH) United States $0.037B 0.00
Mural Oncology (MURA) Ireland $0.036B 0.00
SCYNEXIS (SCYX) United States $0.034B 0.00
Iterum Therapeutics (ITRM) Ireland $0.033B 0.00
Vivos Therapeutics (VVOS) United States $0.032B 0.00
CASI Pharmaceuticals (CASI) China $0.029B 0.00
Cosmos Health (COSM) United States $0.025B 0.00
Enlivex Therapeutics (ENLV) Israel $0.025B 0.00
Natural Alternatives (NAII) United States $0.025B 0.00
Citius Pharmaceuticals (CTXR) United States $0.023B 0.00
Relmada Therapeutics (RLMD) United States $0.021B 0.00
Mangoceuticals (MGRX) United States $0.018B 0.00
Incannex Healthcare (IXHL) Australia $0.017B 0.00
Lipocine (LPCN) United States $0.017B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.017B 0.00
Scienture Holdings (SCNX) United States $0.017B 0.00
Ainos (AIMD) United States $0.017B 0.00
BioLineRx (BLRX) Israel $0.016B 0.00
Mannatech (MTEX) United States $0.016B 0.00
Aptorum Group (APM) United Kingdom $0.014B 0.00
ProPhase Labs (PRPH) United States $0.014B 0.00
TherapeuticsMD (TXMD) United States $0.013B 0.00
Lyra Therapeutics (LYRA) United States $0.012B 0.00
BioVie (BIVI) United States $0.012B 0.00
Phio Pharmaceuticals (PHIO) United States $0.012B 0.00
Ernexa Therapeutics (ERNA) United States $0.012B 0.00
Heatwurx (PCSA) United States $0.011B 0.00
Talphera (TLPH) United States $0.010B 0.00
Traws Pharma (TRAW) United States $0.010B 0.02
Carisma Therapeutics (CARM) United States $0.010B 0.00
NLS Pharmaceutics (NLSP) Switzerland $0.009B 0.00
Kiora Pharmaceuticals (KPRX) United States $0.009B 0.00
Addex Therapeutics (ADXN) Switzerland $0.009B 0.00
Biomerica (BMRA) United States $0.009B 0.00
TransCode Therapeutics (RNAZ) United States $0.009B 0.00
VYNE Therapeutics (VYNE) United States $0.009B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.008B 0.00
Indaptus Therapeutics (INDP) United States $0.008B 0.00
Nuvilex (PMCB) United States $0.007B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.006B 0.00
Aditxt (ADTX) United States $0.005B 0.00
60 Degrees Pharmaceuticals (SXTP) United States $0.005B 0.00
CDT Equity (CDT) United States $0.005B 0.00
InMed Pharmaceuticals (INM) Canada $0.005B 0.00
Clearmind Medicine (CMND) Canada $0.004B 0.00
XORTX Therapeutics (XRTX) Canada $0.004B 0.00
Quoin Pharmaceuticals (QNRX) United States $0.004B 0.00
Alaunos Therapeutics (TCRT) United States $0.004B 0.00
Shuttle Pharmaceuticals Holdings (SHPH) United States $0.004B 0.00
Jaguar Animal Health (JAGX) United States $0.003B 0.00
PainReform (PRFX) Israel $0.003B 0.00
CERo Therapeutics Holdings (CERO) United States $0.003B 0.00
Qualigen Therapeutics (QLGN) United States $0.003B 0.00
Redhill Biopharma (RDHL) Israel $0.003B 0.00
Salarius Pharmaceuticals (SLRX) United States $0.003B 0.00
SciSparc (SPRC) Israel $0.002B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.002B 0.00
SHINECO (SISI) China $0.002B 0.00
Universe Pharmaceuticals INC (UPC) China $0.002B 0.00
TNF Pharmaceuticals (TNFA) United States $0.001B 0.00
Indivior (INDV) United States $0.000B 13.66
4D Pharma (LBPS) United Kingdom $0.000B 0.00
Minerva Neurosciences (NERV) United States $0.000B 1.65
Patheon (PTHN) Netherlands $0.000B 0.00
RVL Pharmaceuticals (RVLP) United States $0.000B 0.00
Silence Therapeutics (SLN) United Kingdom $0.000B 0.00